Adagio Medical (ADGM) Expected to Announce Quarterly Earnings on Monday

Adagio Medical (NASDAQ:ADGM) is projected to post its results before the market opens on Monday, April 6th. Analysts expect Adagio Medical to post earnings of ($0.31) per share for the quarter.

Adagio Medical (NASDAQ:ADGM) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.10.

Adagio Medical Stock Performance

Shares of Adagio Medical stock opened at $1.22 on Monday. Adagio Medical has a 12 month low of $0.63 and a 12 month high of $2.87. The firm has a market capitalization of $25.84 million, a P/E ratio of -0.71 and a beta of 0.12. The company has a current ratio of 0.84, a quick ratio of 0.68 and a debt-to-equity ratio of 1.96. The business has a fifty day simple moving average of $1.02 and a two-hundred day simple moving average of $1.17.

Institutional Investors Weigh In On Adagio Medical

A number of institutional investors have recently made changes to their positions in ADGM. ADAR1 Capital Management LLC purchased a new position in Adagio Medical in the 4th quarter worth approximately $1,206,000. Adage Capital Partners GP L.L.C. lifted its position in Adagio Medical by 18.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,258,501 shares of the company’s stock valued at $1,309,000 after acquiring an additional 200,000 shares in the last quarter. Perceptive Advisors LLC boosted its stake in Adagio Medical by 0.7% during the 2nd quarter. Perceptive Advisors LLC now owns 9,876,576 shares of the company’s stock valued at $12,840,000 after purchasing an additional 64,157 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Adagio Medical during the 4th quarter valued at $1,206,000. Finally, Armistice Capital LLC bought a new stake in shares of Adagio Medical in the 4th quarter worth $497,000. Hedge funds and other institutional investors own 48.08% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ADGM. Weiss Ratings reissued a “sell (d-)” rating on shares of Adagio Medical in a research report on Monday, December 22nd. Lake Street Capital assumed coverage on shares of Adagio Medical in a report on Tuesday, December 2nd. They issued a “buy” rating and a $4.00 price objective on the stock. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.00.

About Adagio Medical

Adagio Medical, Inc (NASDAQ: ADGM) is a medical device company focused on the development and commercialization of a noninvasive system for monitoring intracranial pressure (ICP). The company’s proprietary technology uses tympanic membrane displacement to provide clinicians with real-time estimates of ICP without the risks associated with invasive catheter methods. This approach is designed to improve patient safety, reduce complications, and streamline neurological monitoring in acute and critical care settings.

At the core of Adagio Medical’s pipeline is its ADGM System, which is intended for use in hospitals, emergency departments, and other clinical environments where rapid and accurate assessment of ICP is crucial.